Phase II Study of Levocetirizine in Combination With Capecitabine + Bevacizumab to Overcome Resistance to Anti-angiogenic Therapy in Patients With Refractory Colorectal Cancer
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Levocetirizine (Primary) ; Bevacizumab; Capecitabine
- Indications Colorectal cancer
- Focus Therapeutic Use
- 21 Jul 2016 Status changed from active, no longer recruiting to completed.
- 14 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 06 Nov 2014 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.